Digestive Diseases and Sciences

, Volume 49, Issue 11–12, pp 1971–1976 | Cite as

Factors Influencing the Rate of Fibrosis Progression in Chronic Hepatitis C

  • Conrado M. Fernández-RodriguezEmail author
  • Maria Luisa Gutiérrez
  • Pilar López Serrano
  • José L. Lledó
  • Cecilio Santander
  • Teresa Pérez Fernández
  • Esperanza Tomás
  • Guillermo Cacho
  • Manuel Nevado
  • Maria Luisa Casas


Alcohol consumption, age at infection, and male gender have been identified as risk factors for faster fibrosis progression in patients with chronic hepatitis C (CHC). Yet the influence of liver steatosis, light to moderate alcohol consumption, or iron overload on this progression remains controversial. To analyze the effect of individual risk factors and their interaction on fibrosis progression in a group of patients with CHC and a definite date of infection, we studied 133 consecutive untreated patients. Covariates included were age, body mass index (BMI), gender, age at infection, alcohol intake, serum lipids, glycemia, serum ALT, AST, GGT, iron, and ferritin, grade and stage (METAVIR and Scheuer), and hepatic stainable iron (Perl’s stain). The rate of fibrosis progression was inferred from the METAVIR score. By logistic regression analysis, hepatic steatosis (odds ratio [OR], 3.035; 95% confidence interval [CI], 1.16–7.93), serum ferritin levels higher than 290 ng/ml (OR, 5.5; 1.6–18.65), and light to moderate ethanol intake (1–50 g/day) (OR, 5.22; 1.5–17.67) were independently associated with faster fibrosis progression. There was no effect of interaction between these variables on the rate of fibrosis progression. Liver steatosis, serum ferritin levels, and light to moderate alcohol intake are associated with faster fibrosis progression in chronic hepatitis C. Combination of these factors did not further accelerate this progression. The impact of modification of these factors on progression should be tested in longitudinal studies.

hepatic steatosis fibrosis progression chronic hepatitis C iron overload alcohol intake 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Seeff LB: The natural history of hepatitis C. A quandary. Hepatology 28:1710–1711, 1998CrossRefGoogle Scholar
  2. 2.
    Bataller R, North KE, Brenner DA: Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 37:493–503, 2003CrossRefGoogle Scholar
  3. 3.
    Wright M, Goldin R, Hellier S, et al.: Factor Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 8:1206–1210, 2003CrossRefGoogle Scholar
  4. 4.
    Renou C, Halfon P, Pol S, Cacoub P, Jouve E, Bronowicki JP, Arpurt JP, Rifflet H, Picon M, Causse X, Canva V, Denis J, Tran A, Bourliere M, Ouzan D, Pariente A, Dantin S, Alric L, Cartier V, Reville M, Caillat-Zucman S: Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferases levels. Gut 51:585–590, 2002CrossRefGoogle Scholar
  5. 5.
    Boyer N, Marcelin P: Pathogenesis, diagnosis and management of hepatitis C. J. Hepatol (Suppl 1):113–128, 2000Google Scholar
  6. 6.
    Ghany MG, Kleiner DE, Alter H, et al.: Progression of fibrosis in chronic hepatitis C. Gastroenterology 124:97–104, 2003CrossRefGoogle Scholar
  7. 7.
    Poynard T, Bedossa P, Opolon: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Obsvir, METAVIR, CLINIVIR and DOSCVIR groups. Lancet 22(349):825–832, 1997CrossRefGoogle Scholar
  8. 8.
    Lagging LM, Westin J, Svensson E, Aires N, Dhilon AP, Lindhl M, Norkrans G: Progression of fibrosis in untreated patients with hepatitis C infection. Liver 22:136–144, 2002CrossRefGoogle Scholar
  9. 9.
    Jain SK, Pemberton PW, Smith A, McMahon RF, Buerrows PC, Abotwerat A, Warnes TW: Oxidative stress in chronic hepatitis C: Not just a feature of late stage disease. J Hepatol 36:805–811, 2002CrossRefGoogle Scholar
  10. 10.
    Pietrangelo A: lron, oxidative stress and liver fibrogenesis. J Hepatol 28 (Suppl 1):8–13, 1998CrossRefGoogle Scholar
  11. 11.
    Peters MG, Terrault NA: Alcohol use and hepatitis C. Hepatology 36(5, Suppl 1): S220–S225, 2002PubMedPubMedCentralGoogle Scholar
  12. 12.
    Thorbun D, Curry G, Spooner R, Spence E, Oien K, Halls D, Fox R, McCruden EAB, McSween RMN, Mills PR: The role of iron and hemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 50:248–252, 2002CrossRefGoogle Scholar
  13. 13.
    Serfaty L, Poujol-Robert A, Carbonell N, Chaouzillieres O, Poupon RR, Poupon R: Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hC. Am J Gastroenterol 977:1807–1812, 2002CrossRefGoogle Scholar
  14. 14.
    Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, Truta B, Wright T, Gish R: Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 38:307–314, 2003CrossRefGoogle Scholar
  15. 15.
    Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, Daïkha H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P: Liver fibrosis is not associated with steatosis but with necroinflammation in french patients with hepatitis C. Gut 52:1638–1643, 2003CrossRefGoogle Scholar
  16. 16.
    Ryder SD, on behalf of the Trent Hepatitis C Study Group: Progression of hepatic fibrois in patients with hepatitis C. A prospective repeat liver biopsy study. Gut 53:451–455, 2004CrossRefGoogle Scholar
  17. 17.
    Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24:289–293, 1996CrossRefGoogle Scholar
  18. 18.
    Sindram JW, Marx JJM: Localization of iron in the hepatic acini and bile duct epithelium as a tool for estimation of liver iron overload. Ann NY Acad Sci 526:361–362, 1988CrossRefGoogle Scholar
  19. 19.
    Thomas DL, Astemborski J, Rai RM, Anaia FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection: Host, viral and environmental factors. JAMA 284:450–456, 2000CrossRefGoogle Scholar
  20. 20.
    Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, Rosser BG, Satyanarayana R, Grewal HP, Hewitt WR, Harnois DM, Crook JE, Steers JL, Dickson RC: Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 77:84–92, 2004CrossRefGoogle Scholar
  21. 21.
    Freeman AJ, Law MG, Kaldor JM, Dore GJ: Predicting progression to cirrhosis in chronic hepatitois C virus infection. J Viral Hepat 10:285–293, 2003CrossRefGoogle Scholar
  22. 22.
    Perlemuter G, Letteron P, Carnot F, Zavala F, Pessayre D, Nalpas B, Brechot C: Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatol 39:1020–1027, 2003CrossRefGoogle Scholar
  23. 23.
    Saile B, Matthes N, Knittel T, Ramadori G: Transforming growth factor beta and tumor necrosis facto-alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology 30:196–202, 1999CrossRefGoogle Scholar
  24. 24.
    Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F: Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33:106–115, 2000CrossRefGoogle Scholar
  25. 25.
    Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358–1364, 2001CrossRefGoogle Scholar
  26. 26.
    Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219, 1999CrossRefGoogle Scholar
  27. 27.
    Castera L, Hezode C, Roudot-Thoraval F, et al.: Worsening of steatosis is an independent factor of fibrosis progression in untreated partients with chronic hepatitis C and paired liver biopsies. Gut 52:288–292, 2003CrossRefGoogle Scholar
  28. 28.
    Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell E: Steatosis and chronic hepatitis C: Analysis of fibrosis and stellate cell activation. J Hepatol 34:314–320, 2000CrossRefGoogle Scholar
  29. 29.
    Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J: Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97:2408–2414, 2002CrossRefGoogle Scholar
  30. 30.
    Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639–644, 2003CrossRefGoogle Scholar
  31. 31.
    Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J: Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 125:1695–1704, 2003CrossRefGoogle Scholar
  32. 32.
    Guillyomarc’h A, Mendler MH, Moirand R, et al.: Venesection therapy of insulin resistance-associated hepatic iron overload J Hepatol 53:344–349, 2001CrossRefGoogle Scholar
  33. 33.
    Furutani M, Nakashima T, Sumida Y, Hirohma A, Yoh T, Kakisaka Y, Mitsuyoshi H, Senmaru H, Okanoue T: Insulin resistance/beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int 23:294–299, 2003CrossRefGoogle Scholar
  34. 34.
    Day CP, James OF: Steatohepatitis: A tale of two “hits”? Gastroenterology 114:842–845, 1998CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  • Conrado M. Fernández-Rodriguez
    • 1
    Email author
  • Maria Luisa Gutiérrez
    • 1
  • Pilar López Serrano
    • 1
  • José L. Lledó
    • 1
  • Cecilio Santander
    • 1
  • Teresa Pérez Fernández
    • 1
  • Esperanza Tomás
    • 1
  • Guillermo Cacho
    • 1
  • Manuel Nevado
    • 2
  • Maria Luisa Casas
    • 3
  1. 1.Unit of Gastroenterology and Liver DiseasesFundación Hospital AlcorcónSpain
  2. 2.Pathology UnitFundación Hospital AlcorcónSpain
  3. 3.Laboratory UnitFundación Hospital AlcorcónSpain

Personalised recommendations